Table 1.
Patient characteristics*
| Characteristic | Nomogram development cohort | Validation cohort | ||
|---|---|---|---|---|
| MSKCC MVAC (n = 203) | MSKCC ITP (n = 45) | MSKCC AG-ITP (n = 60) | CALGB 90102 GC-gefitinib (n = 74) | |
| Male:female | 163:40 | 33:12 | 46:14 | 58:16 |
| Median age | 63 | 63 | 62 | 64 |
| Median KPS, % | 80 | 80 | 90 | 90 |
| Visceral disease, % | 49 | 40 | 33 | 69 |
| Bone | 26 | 11 | 10 | 18 |
| Liver | 13 | 13 | 10 | 31 |
| Lung | 26 | 22 | 18 | 43 |
| Risk factors, % | ||||
| 0 | 33 | 55 | 62 | 30 |
| 1 | 45 | 41 | 35 | 65 |
| 2 | 22 | 4 | 3 | 5 |
| Median survival, months (95% CI) | 14.8 (12.1 to 16.7) | 18 (12.0 to 29.7) | 16.4 (14.6 to 22.9) | 12.7 |
| Failed/censored, No. | 184/19 | 37/8 | 53/7 | 68/6 |
*AG-ITP = doxorubicin plus gemcitabine followed by ifosfamide, paclitaxel, and cisplatin; CI = confidence interval; GC = gemcitabine and cisplatin; ITP = ifosfamide, paclitaxel, and cisplatin; KPS = Karnofsky performance status; MSKCC = Memorial Sloan-Kettering Cancer Center; MVAC = methotrexate, vinblastine, doxorubicin, and cisplatin.